Stress is a primary risk factor for several neuropsychiatric disorders. Evidence from
preclinical models and clinical studies of depression have revealed an array of structural …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Background The glutamatergic modulator ketamine has created a blueprint for studying
novel pharmaceuticals in the field. Recent studies suggest that “classic” serotonergic …

Quantifying neural activity in natural conditions (ie conditions comparable to the standard
clinical patient experience) during the administration of psychedelics may further our …

The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …

Ketamine is an N-methyl-d-aspartate antagonist which is increasingly being researched and
used as a treatment for depression. In low doses, it can cause a transitory modification in …

Major depressive disorder is a prevalent and heterogeneous disorder with treatment
resistance in at least 50% of individuals. Most of the initial studies focused on the …

Brain function relies on efficient communications between distinct brain systems. The
pathology of major depressive disorder (MDD) damages functional brain networks, resulting …

The discovery of the rapid-acting antidepressant effects of ketamine has 1) led to a paradigm
shift in our perception of what is possible in treating severe depression; 2) spurred a wave of …

Ketamine is an effective antidepressant, but there is substantial variability in patient
response and the precise mechanism of action is unclear. Neuroimaging can provide …